Previous Page  218 / 300 Next Page
Information
Show Menu
Previous Page 218 / 300 Next Page
Page Background

Notes forming part of consolidated onancial statements (Contd.)

218

Annual Report 2016-17

c) Details of exercise price for stock options outstanding at the end of the year

Scheme

Range of exercise

price

As at March 31, 2017

As at March 31, 2016

No. of Options

outstanding

Weighted

average

remaining

contractual life

(in years)

No. of Options

outstanding

Weighted average

remaining

contractual life

(in years)

Scheme I

2.04 – 9.57

6,583

Note (i)

8,510

Note (i)

Scheme II

12.96 – 48.21

4,603

4.46

7,603

5.46

Scheme III

12.96 – 48.21

238,827

Note (i)

268,394

Note (i)

Scheme IV

22.23 – 61.12

827,944

5.84

970,329

6.76

Scheme V

22.23 – 44.14

116,446

Note (i)

132,534

Note (i)

Scheme VI

22.23 – 30.67

-

-

-

-

Scheme VII

24.17 – 61.12

55,887

5.57

101,469

7.54

Scheme VIII

48.21 – 48.21

-

-

-

-

Scheme IX

54.74 – 54.74

163,777

6.03

174,963

7.04

Scheme X

157.58 – 279.70

988,647

1.51

1,576,020

2.61

Scheme XI

10.00

402,600

1.25

402,600

2.25

Scheme XII

10.00

67,300

0.25

-

-

Note (i) No contractual life is deoned in the scheme

d) Effect of the employee share-based payment plans on the statement of proot and loss and on its onancial

position

Compensation expense arising from equity-settled employee share based payment plans for the year ended March

31, 2017 amounted to

`

59.53 million (Previous year

`

34.48 million). The liability for employee stock options

outstanding as at March 31, 2017 is

`

187.12 million (Previous year

`

147.09 million).

e) Details of stock options granted during the year

The weighted average fair value of the stock options granted during the current year is

`

700.50 (Previous year

`

583.66). The Binomial tree valuation model has been used for computing the weighted average fair value for

stock options granted considering the following inputs:

For the year ended

March 31, 2017

March 31, 2016

Scheme XII

Scheme XI

Weighted average share price

700.50

583.66

Exercise Price

`

10

`

10

Expected Volatility

51.0%

35.08%

/ife of the options granted (Vesting and exercise period)

2.5 Months

3.5 years

Dividend yield

1%

1%

Average risk-free interest rate

7.1%

7.8%

Expected dividend rate

60%

60%